The examination of the effects of Teneligliptin on blood glucose and albuminuria in type 2 diabetic patients with nephropathy, whose glycemic control is insufficient.
- Conditions
- Type 2 diabetic patients with nephropathy
- Registration Number
- JPRN-UMIN000015922
- Lead Sponsor
- Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1)Patient who have a history of allergy to Teneligliptin. 2)Patients who have severe ketosis, diabetic coma, diabetic pre-coma, or type 1 diabetes 3)Patients who have severe infection, surgery, planned surgery, severe trauma. 4)Women who are pregnant, or possibility of pregnant, or wish to pregnant, or lactating. 5)Patients with transit disorder in the digestive tract or peptic ulcer and esophageal varix (this product may irritate affected area.) and patients whom physician judges as inappropriate 6)Patients with a predisposition to severe and habitual constipation (this product may exacerbate constipation) and patients whom physician judges as inappropriate 7)Patients who are considered unsuitable for inclusion by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of HbA1c and urinary albumin excretion
- Secondary Outcome Measures
Name Time Method 1)Parameters of blood glucose (HbA1c, fasting blood glucose, glycoalbumin, insulin) 2)urinary albumin excretion 3)eGFRcreat (calculation by conversion formula of GFRcreat in Japanese), serum creatinine 4)Urinary L-FABP excretion, serum cystatin C (Cys-C), eGFRcys (calculation by conversion formula of eGFRcys in Japanese) 5)Plasma DPP-4 activity, urinary DPP-4 activity 6)Serum lipid (T-cho, LDL, HDL, TG) 7)Blood pressure, pulse